Cell-Penetrating Peptide Nanocomplexes Enable Oral Insulin Delivery That Controls Blood Sugar in Diabetic Mice

Insulin was complexed with GET cell-penetrating peptide via electrostatic interaction to form nanocomplexes. In vitro: transport tested in differentiated Caco-2 intestinal epithelium monolayers; biological activity confirmed via insulin-responsive reporter assays; proteolytic stability assessed. In vivo: oral delivery tested in streptozotocin-induced diabetic mice with serial dosing and blood glucose monitoring.

Millions of people with diabetes inject insulin multiple times daily. An oral insulin pill would dramatically improve quality of life and treatment adherence, but the gut's harsh environment and poor absorption have prevented it. This cell-penetrating peptide approach solves multiple problems at once — protecting insulin from digestion, shuttling it across the intestinal wall, and creating intracellular depots for sustained release. The simplicity of the complexation platform also makes it potentially applicable to other peptide drugs.

Oral peptide delivery is one of the biggest unsolved problems in drug development. While oral semaglutide (Rybelsus) cracked the code for GLP-1 using an absorption enhancer, insulin is a larger and more fragile molecule that has resisted similar approaches. Cell-penetrating peptide nanocomplexes represent a different strategy — actively transporting insulin through cells rather than just enhancing passive absorption. If this translates to humans, it could transform diabetes management and serve as a platform for oral delivery of other injectable peptide drugs.

Mouse model only; Caco-2 model doesn't fully replicate human intestine; oral bioavailability not quantified; long-term safety unknown; STZ model represents type 1 diabetes only.